Literature DB >> 16464465

A new clinically relevant approach to expand myelin specific T cells.

Nathalie Arbour1, Réjean Lapointe, Philippe Saikali, Ellie McCrea, Tommy Regen, Jack P Antel.   

Abstract

Human self-reactive T cells are potentially involved in many autoimmune diseases. Although ex vivo detection of self-reactive T cells is possible, exhaustive functional characterization of these cells is impeded by their low frequency. In vitro expansion of antigen (Ag) specific T cells is typically achieved by using autologous (fresh or frozen) irradiated peripheral blood mononuclear cells (PBMCs), EBV-immortalized B cells or dendritic cells in the presence of Ag. These approaches require a large blood volume. We explored a method successfully applied for tumor specific T cells using in vitro expanded autologous B cells. PBMCs were stimulated with irradiated CD40L-expressing fibroblasts and IL-4, resulting in an enriched population of B cell that expressed high levels of MHC and co-stimulatory molecules, essential hallmarks of antigen presenting cells (APCs). Expanded B cells were loaded with Ag, irradiated and then used as APCs to stimulate T cells. The specificity of T cell lines was assessed by comparing their proliferation and IFN-gamma secretion when cultured with antigen-loaded B cells vs. unloaded B cells. T cell lines exhibiting antigen-specific proliferation and/or IFN-gamma secretion were expanded. Using this method, MBP and MOG specific CD4(+) and CD8(+) T cell lines were obtained from multiple donors in comparable numbers to those obtained using the traditional approach (i.e. fresh PBMCs as APCs) and were kept in culture for many weeks. We have shown that myelin specific CD4(+) and CD8(+) T cells can be expanded from a relatively small volume of blood (50-100 ml) from multiple donors using expanded B cells as APCs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16464465     DOI: 10.1016/j.jim.2005.12.009

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  7 in total

Review 1.  Regulatory T cells as therapeutic targets in rheumatoid arthritis.

Authors:  Jonathan H Esensten; David Wofsy; Jeffrey A Bluestone
Journal:  Nat Rev Rheumatol       Date:  2009-10       Impact factor: 20.543

2.  B cell-derived IL-15 enhances CD8 T cell cytotoxicity and is increased in multiple sclerosis patients.

Authors:  Raphael Schneider; Alma Nazlie Mohebiany; Igal Ifergan; Diane Beauseigle; Pierre Duquette; Alexandre Prat; Nathalie Arbour
Journal:  J Immunol       Date:  2011-09-12       Impact factor: 5.422

3.  Defining a new biomarker for the autoimmune component of Multiple Sclerosis: Th40 cells.

Authors:  Dan M Waid; Teri Schreiner; Gisela Vaitaitis; Jessica R Carter; John R Corboy; David H Wagner
Journal:  J Neuroimmunol       Date:  2014-03-15       Impact factor: 3.478

4.  Capturing T Lymphocytes' Dynamic Interactions With Human Neural Cells Using Time-Lapse Microscopy.

Authors:  Florent Lemaître; Ana Carmena Moratalla; Negar Farzam-Kia; Yves Carpentier Solorio; Olivier Tastet; Aurélie Cleret-Buhot; Jean Victor Guimond; Elie Haddad; Nathalie Arbour
Journal:  Front Immunol       Date:  2021-04-22       Impact factor: 7.561

5.  Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand expression in multiple sclerosis.

Authors:  Camille L Pittet; Jia Newcombe; Alexandre Prat; Nathalie Arbour
Journal:  J Neuroinflammation       Date:  2011-11-08       Impact factor: 8.322

Review 6.  The CD40-CD40L Dyad in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis.

Authors:  Suzanne A B M Aarts; Tom T P Seijkens; Koos J F van Dorst; Christine D Dijkstra; Gijs Kooij; Esther Lutgens
Journal:  Front Immunol       Date:  2017-12-12       Impact factor: 7.561

Review 7.  Revisiting T Cell Tolerance as a Checkpoint Target for Cancer Immunotherapy.

Authors:  Simone Nüssing; Joseph A Trapani; Ian A Parish
Journal:  Front Immunol       Date:  2020-09-23       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.